Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
      Description

      This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.

      Conditions
      RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid CancerRET-altered Colon CancerRET-altered Solid TumorsLung NeoplasmCarcinoma, Non-Small-Cell LungThyroid DiseasesThyroid NeoplasmThyroid Cancer, PapillaryCarcinoma, NeuroendocrineRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseaseCarcinoma, BronchogenicBronchial NeoplasmsEndocrine System DiseasesEndocrine Gland NeoplasmHead and Neck NeoplasmsAdenocarcinoma, PapillaryAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms, Nerve TissueColonic NeoplasmsColorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmDigestive System DiseaseGastrointestinal DiseaseColonic DiseasesIntestinal Disease
      Talk to us
      ACTIVE_NOT_RECRUITING
      Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
      Description

      This phase II trial studies the effect of selpercatinib given before surgery in treating patients with thyroid cancer whose tumors have RET alterations (changes in the genetic material \[deoxyribonucleic acid (DNA)\]). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving selpercatinib before surgery may help shrink the tumors and help control the disease.

      Conditions
      Malignant Thyroid Gland NeoplasmPoorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaThyroid Gland Anaplastic CarcinomaThyroid Gland Medullary CarcinomaThyroid Gland Papillary CarcinomaThyroid Gland Squamous Cell Carcinoma
      Talk to us